🇺🇸 FDA
Patent

US 10478410

Process to prepare treprostinil, the active ingredient in Remodulin®

granted A61KA61K31/192A61P

Quick answer

US patent 10478410 (Process to prepare treprostinil, the active ingredient in Remodulin®) held by United Therapeutics Corporation expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/192, A61P, A61P1/00, A61P1/14